In order to provide targeted diagnostic and therapeutic advice to patients suffering from NASH or HCC, we developed nomogram models for the NASH patients (utilizing FDX1, LIPT1, and PDHP expression) and the NASH to HCC patients (utilizing FDX1, DBT, GCSH, SLC31A1, and DLAT expression) (Figure 3a,e). This evidence concerns the gene DLAT and metabolic dysfunction-associated steatohepatitis.